Truist Financial Boosts CG Oncology (NASDAQ:CGON) Price Target to $75.00

CG Oncology (NASDAQ:CGON) had its price objective boosted by research analysts at Truist Financial from $66.00 to $75.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 46.83% from the stock’s current price.

A number of other equities analysts have also recently commented on the company. Wedbush started coverage on CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 target price on the stock. Royal Bank Of Canada lifted their price objective on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a report on Friday, January 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $82.00 price target on shares of CG Oncology in a report on Monday, January 12th. Finally, Piper Sandler increased their price objective on shares of CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CG Oncology currently has an average rating of “Moderate Buy” and an average price target of $68.58.

CG Oncology Trading Up 1.4%

Shares of CGON opened at $51.08 on Tuesday. The firm has a market cap of $4.12 billion, a PE ratio of -25.04 and a beta of 1.31. The firm has a fifty day simple moving average of $46.42 and a two-hundred day simple moving average of $39.41. CG Oncology has a 1-year low of $14.80 and a 1-year high of $57.88.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, hitting the consensus estimate of ($0.57). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.07 million. As a group, research analysts forecast that CG Oncology will post -1.31 EPS for the current fiscal year.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $41.43, for a total transaction of $41,430.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. Additional details regarding this sale are available in the official SEC disclosure.

Hedge Funds Weigh In On CG Oncology

Several large investors have recently modified their holdings of CGON. Whittier Trust Co. of Nevada Inc. bought a new stake in CG Oncology in the fourth quarter worth $27,000. Strengthening Families & Communities LLC purchased a new stake in CG Oncology in the 3rd quarter worth about $40,000. Comerica Bank boosted its position in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares during the period. Winthrop Capital Management LLC bought a new position in shares of CG Oncology during the second quarter valued at approximately $38,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after buying an additional 433 shares during the period. Institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.